Medication pipeline active
- Presentations at APSARD 2026 covered new ADHD medications, including discussions of mechanisms and efficacy. - A Psychiatric Times overview says ADHD remains a prominently featured area in the psychiatric drug-development pipeline. - A busier treatment pipeline will increase options but also complexity for families deciding between medications and non-pharmacologic supports (psychiatrictimes.com) (psychiatrictimes.com).
Attention-deficit/hyperactivity disorder treatment is getting more crowded, with APSARD’s January 15-18, 2026 meeting spotlighting new drug data and a wider psychiatric pipeline still featuring ADHD. (psychiatrictimes.com) (apsard.org) (psychiatrictimes.com) ADHD medicines work by changing the brain chemicals tied to attention, impulse control, and activity level. At APSARD 2026 in San Diego, Massachusetts General Hospital psychiatrist Timothy Wilens said clinicians are watching drugs that may also address anxiety, depression, executive dysfunction, and sleep. (psychiatrictimes.com) (apsard.org) One drug already on the market, viloxazine extended release, sold as Qelbree, is approved by the Food and Drug Administration for adults and children age 6 and older. Wilens said APSARD posters from an ongoing naturalistic study followed patients in real clinics, including people with anxiety and depression, and showed improvement in depression, anxiety, and sleep. (accessdata.fda.gov) (psychiatrictimes.com) Another drug, centanafadine, is still investigational and not approved by the Food and Drug Administration. Wilens said phase 3 data in children and adolescents showed ADHD improvement, especially at the higher dose, and described the drug as affecting dopamine, norepinephrine, and serotonin. (psychiatrictimes.com) (clinicaltrials.gov) The pipeline is active beyond one conference. Psychiatric Times’ review of fourth-quarter 2025 pipeline coverage said ADHD accounted for 18.8% of the disease areas featured, behind schizophrenia at 31.3% and Alzheimer disease and major depressive disorder at 25% each. (psychiatrictimes.com) Clinicians are also preparing for harder treatment choices, not just more prescriptions. A separate APSARD 2026 presentation from Kevin Muthu and David Osser laid out an adult ADHD medication algorithm that addressed formulation choice, dosing, cardiovascular screening, substance use disorder, psychosis, bipolar disorder, and when to use nonstimulants. (psychiatrictimes.com) That complexity lands in a large patient population. The Centers for Disease Control and Prevention says 7 million U.S. children ages 3 to 17, or 11.4%, had ever received an ADHD diagnosis in 2022, and a National Center for Health Statistics brief put the 2020-2022 prevalence at 11.3% for children ages 5 to 17. (cdc.gov 1) (cdc.gov 2) APSARD’s 2026 program showed the debate is not only about which drug comes next. Sessions covered cognitive behavioral therapy for ADHD, stimulant safety, telehealth, pregnancy, sleep, coaching, school stigma, and access to culturally responsive services for youth and emerging adults. (apsard.org) (psychiatrictimes.com) Researchers at the same meeting also pushed back on one long-running fear about treatment. Psychiatric Times’ APSARD coverage said presenters Brooke Molina, Brian D’Onofrio, and Ryan Sultan reported that childhood stimulant treatment did not appear to predict later substance use disorder in the research reviewed. (psychiatrictimes.com) The near-term story is not a single new pill replacing older ones. It is a field adding more stimulant and nonstimulant options, more comorbidity questions, and more tradeoffs for families and clinicians to sort through visit by visit. (psychiatrictimes.com 1) (psychiatrictimes.com 2)
